Finance

Lists
AVTX:NASDAQ
Avalo Therapeutics Inc
$19.47
-1.52%
(-0.30) 1D
$19.47
0.00% (0.00)
After hours
Closed: Aug 11, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AVTX...
Open
$19.67
High
$20.00
Low
$18.86
Mkt. cap
1.04B
Avg. vol.
1.06M
Volume
714.96K
52-wk high
$24.27
52-wk low
$8.41
EPS
-$4.75
Beta
0.80
Shares outstanding
53.63M
No. of employees
33
Open
$19.67
High
$20.00
Low
$18.86
Mkt. cap
1.04B
Avg. vol.
1.06M
Volume
714.96K
52-wk high
$24.27
52-wk low
$8.41
EPS
-$4.75
Beta
0.80
Shares outstanding
53.63M
No. of employees
33
News stories
From web sources and news partners
About Avalo Therapeutics Inc
CEO-
Employees33
Founded2011
HeadquartersRockville, Pennsylvania, United States
SectorBiotechnology
Websiteavalotx.com
Analyst ratings
Based on 10 analysts giving stock ratings to AVTX in the past 3 months
Strong buy
Buy
10
Hold
0
Sell
0
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for AVTX in the last 3 months.
Highest
Current $19.47
$58.00 (+197.89%)
Average
$42.44 (+117.98%)
Lowest
$30.00 (+54.08%)
Analyst
Recommendation
Action
Price target
Projected
Date
Yatin Suneja
Guggenheim
Buy
Reiterated
$48.00
+146.5%
08/06/2026
Julian Harrison
BTIG
Buy
Maintained
$58.00
+197.9%
08/06/2026
Alec Stranahan
Bank of America Securities
Buy
Reiterated
$35.00
+79.8%
08/07/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
$30.00
+54.1%
08/07/2026
Thomas Smith
Leerink Partners
Buy
Initiated
$38.00
+95.2%
07/06/2026
Stacy Ku
TD Cowen
Buy
Maintained
-
-
06/11/2026
Alex Thompson CFA
Stifel Nicolaus
Buy
Maintained
$39.00
+100.3%
05/15/2026
Robert Driscoll
Wedbush
Buy
Reiterated
$34.00
+74.6%
05/14/2026
Joseph Catanzaro
Mizuho Securities
Buy
Maintained
$45.00
+131.1%
05/14/2026
Jason Butler
Citizens JMP
Buy
Maintained
$55.00
+182.5%
05/14/2026
Yasmeen Rahimi
Piper Sandler
Buy
Reiterated
$60.00
+208.2%
05/11/2026
Andy Chen
Wolfe Research
Buy
Initiated
$48.00
+146.5%
04/08/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
59.00K
-
-
Cost of goods sold
9.99M
8.78M
10.15M
19.03M
Cost of revenue
9.99M
8.78M
10.15M
19.03M
Research and development expenses
3.63M
4.48M
3.90M
4.39M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.58M
6.53M
6.85M
8.10M
Operating expense
9.21M
11.02M
10.75M
12.49M
Total operating expenses
19.20M
19.80M
20.90M
31.52M
Operating income
-19.20M
-19.74M
-20.90M
-31.52M
Other non operating income
-12.53M
5.17M
480.00K
-7.58M
EBT including unusual items
-30.61M
-13.59M
-19.62M
-36.34M
EBT excluding unusual items
-30.61M
-13.59M
-19.62M
-36.34M
Income tax expense
11.00K
130.00K
12.00K
18.00K
Effective tax rate
-0.04%
-0.96%
-0.06%
-0.05%
Other operating expenses
-
-
-
-
Net income
-30.62M
-13.72M
-19.63M
-36.36M
Net profit margin
-
-23,254.24%
-
-
Earnings per share
-2.19
-0.37
-0.98
-0.83
Interest and investment income
1.12M
984.00K
803.00K
2.76M
Interest expense
-
-
-
-
Net interest expenses
1.12M
984.00K
803.00K
2.76M
Depreciation and amortization charges
-
-
-
-
EBITDA
-19.14M
-19.73M
-20.88M
-31.50M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps